Management of Obesity in the National Health and Nutrition Examination Survey (NHANES), 2007–2008

Samaranayake, NR; Ong, Kwok Leung; Leung, R; Cheung, Bmy

doi:10.1016/j.annepidem.2012.01.001

Cited by 48 publications

(36 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consistent with the present study using prescription data in a US primary care setting, data from two US national surveys have also indicated that the use of pharmacotherapy for weight loss among eligible patients is low 8, 9. In a retrospective cross‐sectional analysis of pharmacy data from the 2002–2007 US Medical Expenditure Panel Survey, only 0.61% of eligible patients used weight‐loss drugs 8.…”

Section: Discussionsupporting

confidence: 84%

Characteristics of patients potentially eligible for pharmacotherapy for weight loss in primary care practice in the United States

Zhang

Manne

Jiao

2016

Obesity Science & Practice

View full text Add to dashboard Cite

SummaryObjectiveTo describe the characteristics of real‐world patients potentially eligible for adjunctive pharmacotherapy for weight loss.MethodsPatients from the GE Centricity electronic medical record database were selected if they had body mass index (BMI) ≥30 or ≥27 to <30 kg m−2 with ≥1 obesity‐associated comorbidity (hypertension, dyslipidemia, or type 2 diabetes) from 2002–2011; were aged ≥18 years and had ≥12 months of continuous enrollment before and after the date of first eligible BMI recorded (index date). Descriptive statistics and logistic regression were used for analysis.ResultsOf the 1,835,541 patients with overweight or obesity included, comorbidities were common (hypertension [55.4%], dyslipidemia [36.1%] and type 2 diabetes [13.4%]). The percentage of patients who received pharmacotherapy for weight loss was 0.7% within 12 months after the index date. Patients who received pharmacotherapy had higher BMI (median, 33.6 vs. 31.3 kg m−2), were younger (median, 42 vs. 52 years), primarily women (84.3 vs. 58.2%), commercially insured (70.1 vs. 50.4%) and had more frequent use of antidepressants (30.8 vs. 14.1%) and non‐steroidal anti‐inflammatory drugs (21.7 vs. 12.0%) than those who did not at baseline (all P values < 0.0001).ConclusionsFew eligible patients received pharmacotherapy for weight loss. Patients who received pharmacotherapy tended to be heavier, younger, female, commercially insured, and used more antidepressants and non‐steroidal anti‐inflammatory drugs.

show abstract

Section: Discussionsupporting

confidence: 84%

Characteristics of patients potentially eligible for pharmacotherapy for weight loss in primary care practice in the United States

Zhang

Manne

Jiao

2016

Obesity Science & Practice

View full text Add to dashboard Cite

show abstract

“…8 Only 2% of American adults who are eligible for obesity pharmacotherapy actually receive them from a provider, even though nearly half of Americans meet the medical obesity pharmacotherapy criteria. 9,10 Numerous barriers preclude healthcare providers from adequately prescribing weight loss medications. First, inadequate training in medical schools and residency programs leads to a lack of confidence in prescribing such medications.…”

Section: Introductionmentioning

confidence: 99%

Updates on obesity pharmacotherapy

Velazquez

Apovian

2018

Annals of the New York Academy of Sciences

View full text Add to dashboard Cite

Obesity is a chronic, relapsing disease that necessitates a multidisciplinary approach to management. Behavioral changes are the foundation to management, but adjunctive therapy is often warranted, including pharmacologic therapies and/or bariatric surgery. Until recently, treatment options included only short-term therapy (ࣘ12 weeks), and paths beyond that schedule were challenging, as knowledge of the biology of obesity was lacking. With increased recognition of obesity as a chronic, complex medical disease, newer agents have been approved as long-term therapy, and the cornerstone of treatment is chronic behavior and lifestyle change. In the last decade, the Food and Drug Administration (FDA) has approved several new weight loss medications for the chronic management of obesity. In this review paper, we provide the latest updates on obesity pharmacotherapy. The main areas we will cover include (1) pharmacological management of obesity, (2) a review of FDA-approved weight loss medications, (3) comanagement of obesity and its metabolic sequelae (type 2 diabetes mellitus, hypertension, and dyslipidemia), and (4) obesity-centric prescribing for mental illness, neurological disorders, and contraceptive planning.

show abstract

“…Scenario 1 (status quo) represented current rates of obesity and diet and exercise among the population (Table ). We assumed no AOM use under the status quo because less than 2% of individuals eligible for AOM receive such therapies . In scenario 2 (15% uptake), we assumed that 15% of eligible treatment‐naïve individuals initiated treatment with currently available AOM for chronic weight management (i.e., liraglutide 3.0 mg, lorcaserin, phentermine/topiramate, and naltrexone/bupropion) in each model cycle starting in 2019.…”

Section: Methodsmentioning

confidence: 99%

The Societal Value of Broader Access to Antiobesity Medications

Kabiri¹,

Ward²,

Ramasamy

et al. 2019

Obesity

View full text Add to dashboard Cite

Objective Obesity and its complications place an enormous burden on society. Yet antiobesity medications (AOM) are prescribed to only 2% of the eligible population, even though few individuals can sustain weight loss using other strategies alone. This study estimated the societal value of greater access to AOM. Methods By using a well‐established simulation model (The Health Economics Medical Innovation Simulation), the societal value of AOM for the cohort of Americans aged ≥ 25 years in 2019 was quantified. Four scenarios with differential uptake among the eligible population (15% and 30%) were modeled, with efficacy from current and next‐generation AOM. Societal value was measured as monetized quality of life, productivity gains, and savings in medical spending, subtracting the costs of AOM. Results For the 217 million Americans aged ≥ 25 years, AOM generated $1.2 trillion in lifetime societal value under a conservative scenario (15% annual uptake using currently available AOM). The introduction of next‐generation AOM increased societal value to $1.9 to $2.5 trillion, depending on uptake. Finally, societal value was higher for younger individuals and Black and Hispanic individuals compared with White individuals. Conclusions This study suggests that AOM provide substantial gains to patients and society. Policies promoting broader clinical access to and use of AOM warrant consideration to reach national goals to reduce obesity.

show abstract

Management of Obesity in the National Health and Nutrition Examination Survey (NHANES), 2007–2008

Abstract: Although obesity is highly prevalent, only a small percentage of obese Americans are on anti-obesity medication. The withdrawal of sibutramine would have minimal impact on the general population. There is a need for more lifestyle changes in the majority of obese individuals.

Cited by 48 publications

References 26 publications

Characteristics of patients potentially eligible for pharmacotherapy for weight loss in primary care practice in the United States

Characteristics of patients potentially eligible for pharmacotherapy for weight loss in primary care practice in the United States

Updates on obesity pharmacotherapy

The Societal Value of Broader Access to Antiobesity Medications

Contact Info

Product

Resources

About